Document is current

Article History

Received: 19 May 2023

Accepted: 8 September 2023

First Online: 12 October 2023

Declarations

:

: Richard MacIsaac: Has received research grants from Novo Nordisk, Servier, Medtronic, The Rebecca Cooper Medical Research Foundation, St Vincent’s Research Foundation, The Juvenile Diabetes Research Foundation, Grey Innovations, The Diabetes Australia Research Trust/Program and The National Health and Medical Research Council of Australia. Also received honoraria for lectures from Eli Lilly, Novo Nordisk, Sanofi Aventis, AstraZeneca, Merck Sharp & Dohme, Norvartis and Boehringer Ingelheim and has been or is on the advisory boards for Novo Nordisk, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, AstraZeneca and Merck Shape and Dohme. Travel support has been supplied by Novo Nordisk, Sanofi, Boehringer Ingelheim and AstraZeneca. Has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Sanofi, Bayer, Johnson-Cilag and AbbVie. Gary Deed: Has provided Advisory Board consultancy to Eli Lilly regarding tirzepatide, has provided medical education consultancy or been on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly Australia, MSD Australia, Novo Nordisk and Sanofi-Aventis Australia, and provides educational support in diabetes management. Michael D’Emden: Has received honoraria for attendance at national advisory boards, presentations and/or support to attend international meetings from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Novartis, Abbott, Novo Nordisk, Servier and Bayer. Elif I. Ekinci: Has been a member of advisory boards for Eli Lilly, Sanofi, Pfizer, and Bayer; income received is donated to EE’s institution for diabetes research. Speakers fees for presentations for Eli Lilly, Bayer and Sanofi have been donated to EE’s institution for diabetes research. EE’s institution has received research funding from Eli Lilly, Boehringer, Sanofi, Novo Nordisk, Gilead and Insulet. Samantha Hocking: Has received research grants from Novo Nordisk, The Diabetes Australia Research Trust/Program and The National Health and Medical Research Council of Australia. Also received honoraria for lectures from Eli Lilly, Boehringer Ingelheim, Novo Nordisk, Sanofi Aventis, AstraZeneca, Gilead, Inova and Merck Sharp & Dohme and has been or is on the advisory boards for Novo Nordisk, Eli Lilly, AstraZeneca, Inova and Pfizer. Has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Merck Sharp & Dohme. Co-authorship of manuscripts assisted by medical writing from Novo Nordisk. Priya Sumithran: Has received research grants paid to the Institution from National Health and Medical Research Council. Co-authorship of manuscripts assisted by medical writing from Novo Nordisk. Roy Rasalam: Has provided medical education consultancy or been on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly Australia, MSD Australia, Novo Nordisk and Sanofi-Aventis Australia.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.